Research Topics
| Roger PomerantzSummaryAffiliation: Thomas Jefferson University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The HIV-1 Vif protein: a paradigm for viral:cell interactionsR J Pomerantz
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Cell Mol Life Sci 60:2017-9. 2003- Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradicationRoger J Pomerantz
Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, PA 19107, USA
Arch Immunol Ther Exp (Warsz) 52:297-306. 2004..These will include induction of HIV-1 latent proviruses, suppression of residual viral replication and destruction of long-lived cellular sanctuaries, such astissue-bound macrophages... - Twenty years of therapy for HIV-1 infectionRoger J Pomerantz
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Nat Med 9:867-73. 2003..This article summarizes the accomplishments thus far and what lies ahead in our struggle to improve the treatment of, and possibly eliminate, HIV-1 infection... - Effects of HIV-1 Vpr on neuroinvasion and neuropathogenesisRoger J Pomerantz
Biochemistry and Molecular Pharmacology, Division of Infectious Disease and Environmental Medicine, Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
DNA Cell Biol 23:227-38. 2004..One of these proteins, the accessory HIV-1 protein Vpr, is a critical moiety in these studies, and will be discussed in this article... - RNA interference:a potential novel therapeutic combating HIV-1 in the central nervous systemRoger J Pomerantz
Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, PA 19107, USA
Arch Immunol Ther Exp (Warsz) 52:401-9. 2004..Thus, we now seek to combine our background in molecular therapeutics and RNAi with our long-standing interest in HIV-1 neuropathogenesis to target the CNS using siRNAs... - First International Workshop on HIV-1 Persistence During TherapyRoger Pomerantz
Center for Human Virology and Biodefense, Philadelphia, Pennsylvania, USA
HIV Clin Trials 5:40-9. 2004 - Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathwaysWei Chen
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Virology 334:59-73. 2005..Thus, these data suggest rationally-designed, molecular targets for potential anti-HIV-1 neuroprotection... 
Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cellsRene Daniel
Thomas Jefferson University, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, JAH Suite 321, 1020 Locust St, Philadelphia, PA 19107, USA
J Virol 79:2058-65. 2005..Taken together, these data suggest that the effect(s) of caffeine on HIV-1 transduction is mediated at least partly by the inhibition of the ATR pathway but is not dependent on the caffeine-mediated inhibition of cell cycle checkpoints...- Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infectionElena I Marusich
Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Center for Human Virology and Biodefense, Thomas Jefferson University, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Virology 332:258-71. 2005.... - IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAARTFeng Xiang Wang
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Clin Invest 115:128-37. 2005.... - Pentoxifylline suppresses transduction by HIV-1-based vectorsJohanna A Smith
Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Intervirology 50:377-86. 2007.... - Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strainsRajnish S Dave
Dorrance H. Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, 1020 Locust St, Suite 329, Philadelphia, PA 19107, USA
J Virol 78:13687-96. 2004.... - Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaquePhilip M McKenna
Department of Microbiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
J Virol 78:13455-9. 2004..6P). There was no evidence of CD4(+) T-cell loss, and plasma viremia was controlled to undetectable levels by 6 weeks postchallenge and has remained suppressed out to 22 weeks postchallenge... - Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agentsJoseph Kulkosky
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS Res Hum Retroviruses 20:497-505. 2004.... - Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectorsZahida Parveen
Dorrance H Hamilton Laboratories, Center for Human Virology and Biodefense, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, 1020 Locust St, Ste 329, Philadelphia, PA 19107, USA
J Virol 78:6480-8. 2004..These studies should provide further insight into the design and development of novel molecular approaches to block HIV-1 replication and to construct a new generation of SNV-based vectors... - Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspasesEdward A Acheampong
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
J Virol 79:4257-69. 2005..The results of this study demonstrate that Nef likely contributes to the neuroinvasion and neuropathogenesis of HIV-1, through its effects on select cellular processes, including various apoptotic cascades... - Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthinesGiuseppe Nunnari
The Dorrance H. Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Virology 335:177-84. 2005..These data reveal the feasibility of therapeutic approaches targeting host cell proteins and further support the hypothesis that ATR and ATM proteins are involved in retroviral DNA integration... - Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neuronsMuhammad Mukhtar
The Dorrance H. Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Brain Res Mol Brain Res 135:48-57. 2005..The ability to selectively down-modulate the surface expression of CXCR4 in CNS cells may allow for the development of clinical molecular therapy strategies against HIV-1-related neurodegenerative disorders and neuroinvasion... - Hide-and-seek: the challenge of viral persistence in HIV-1 infectionLuc Geeraert
Tibotec BVBA, BE 2800 Mechelen, Belgium
Annu Rev Med 59:487-501. 2008..A more detailed understanding of the basic mechanisms underlying the establishment and long-term maintenance of HIV-1 reservoirs will be critical in developing new eradication approaches... - Effects of highly active antiretroviral therapy on HIV-1-associated oral complicationsZahida Parveen
Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Curr HIV Res 5:281-92. 2007..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented... - HIV-1 Vpr potently induces programmed cell death in the CNS in vivoXiaodong Cheng
The Dorrance H Hamilton Laboratories, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
DNA Cell Biol 26:116-31. 2007..We propose that this, in expensive animal model, may be of value to design-targeted neuroprotective therapeutics... - siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effectsRajnish S Dave
The Dorrance H Hamilton Laboratories, Division of Infectious Diseases, Center for Human Virology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Virology 348:489-97. 2006..These studies demonstrate the utility of E3L-specific siRNAs as potent antiviral agents for small pox and related pox viruses... - Anti-HIV-1 microbicides -- 'chemical condoms' designed to limit the scourge of the HIV-1 pandemicStephen J Scholand
Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Curr Pharm Des 11:3747-56. 2005..Important features include safety, efficacy and user acceptability. This review summarizes some of the important products in the development pipeline... - IL-7 as a potential therapy for HIV-1-infected individualsGiuseppe Nunnari
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Expert Opin Biol Ther 5:1421-6. 2005..In this present review, different immunological and virological properties of IL-7 are discussed, along with the possibility of its use as part of a combined antiretroviral-immune rationally based HIV-1 eradication approach... - T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disordersMuhammad Mukhtar
The Jefferson Institute for Research in Human Virology and Biodefense Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Neuromolecular Med 7:265-73. 2005.... - Seminal reservoirs during an HIV type 1 eradication trialGiuseppe Nunnari
Institute for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS Res Hum Retroviruses 21:768-75. 2005..This study suggests viral compartmentalization of the semen microenvironment after an intensification and stimulatory HIV-1 eradication protocol, with evidence of viral evolution... - Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infectionGiuseppe Nunnari
Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Neurovirol 11:319-28. 2005.... - HIV type 1 cervicovaginal reservoirs in the era of HAARTGiuseppe Nunnari
Institute for Human Virology and Biodefense, Thomas Jefferson University, Jefferson Alumni Hall, Philadelphia, Pennsylvania 19107, USA
AIDS Res Hum Retroviruses 21:714-8. 2005..Nonetheless, the presence of even low cell-free HIV-1 RNA in cervicovaginal secretions continues to suggest the importance of practicing protected sex, even in the era of HAART... - Antiretroviral therapy in the developing worldLalita Chulamokha
Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
J Neurovirol 11:76-80. 2005 - Current status of gene therapy strategies to treat HIV/AIDSDavid S Strayer
Department of Pathology, Jefferson Medical College, 1020 Locust Street, Room 251, Philadelphia, PA 19107, USA
Mol Ther 11:823-42. 2005..This review focuses on the newest developments in these areas and provides a strong basis for renewed optimism that gene therapy will have an important role to play in treating people infected with HIV-1... - The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytesJianhua Fang
The Dorrance H Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Virology 336:299-307. 2005..Thus, these data suggest a molecular mechanism(s) for restricted replication in astrocytes as a potential low-level site of residual HIV-1 in vivo... - ATM: HIV-1's Achilles heel?Rene Daniel
Nat Cell Biol 7:452-3. 2005 - HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and hostElias G Argyris
Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Disease and Environmental Medicine, Dept. of Medicine, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Trends Microbiol 12:145-8. 2004 - HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathyYan Xu
Dorrance H Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Proc Natl Acad Sci U S A 101:7070-5. 2004..These analyses suggest molecular mechanisms for the induction of apoptosis relating to the exposure of viral and host cell factors and rationally designed approaches toward neuroprotection... - In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 monthsMichele Di Mascio
Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
J Virol 77:2271-5. 2003..This range of half-lives is consistent with the estimated half-life of the latent HIV-1 reservoir in the peripheral blood. Those patients without decay of viral load in plasma may have significant cryptic HIV-1 residual replication... - Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cellsEdward Acheampong
The Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferdon University, Philadelphia, Pennsylvania 19107, USA
Virology 304:222-34. 2002..Thus, these studies demonstrate ethanol's potential for inducing apoptosis of human MVECs with relevant HIV-1-specific proteins and suggest a potential synergistic effect in augmenting HIV-1 neuroinvasion and neuropathogenesis in vivo... - Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapyJoseph Kulkosky
Dorrance H Hamilton Laboratories, Center for Human Virology and Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Clin Infect Dis 35:1520-6. 2002..These studies and new approaches to activating latent virus in resting CD4+ T cells are reviewed and critically analyzed in the present report. Development of novel IAT may lead to long-term remission or viral eradication in the future... - Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapyJoseph Kulkosky
Dorrance Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Infect Dis 186:1403-11. 2002..Additional experimental approaches must be developed if HIV-1 eradication is to become possible in patients receiving virally suppressive HAART... - HIV-1 reservoirsRoger J Pomerantz
Dorrance H Hamilton Laboratory, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Clin Lab Med 22:651-80, vi. 2002..The advent of combination therapeutics for HIV-1 (i.e., highly active antiretroviral therapy [HAART]) has led to dramatic reductions in viral replication in vivo and morbidity and mortality, at least in the developed world... - Eliminating HIV-1 reservoirsRoger J Pomerantz
Thomas Jefferson University, Philadelphia, PA 19107, USA
Curr Opin Investig Drugs 3:1133-7. 2002..In understanding the molecular pathogenesis of HIV-1 disease, one can potentially target these cellular reservoirs of HIV-1 persistence... - RNA interference meets HIV-1: will silence be golden?Roger J Pomerantz
Nat Med 8:659-60. 2002 - Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGNMuhammad Mukhtar
The Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Virology 297:78-88. 2002..These data will assist in further understanding lentiviral entry into the CNS... - Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissueHarris Goldstein
Departments of Pediatrics and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Infect Dis 185:1425-30. 2002..In addition, these data indicate that SV40-derived vectors may provide a system capable of efficient in vivo gene delivery... - Lentiviral expression of HIV-1 Vpr induces apoptosis in human neuronsCharvi A Patel
The Dorrance H Hamilton Laboratories, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Neurovirol 8:86-99. 2002..Thus, Vpr delivered intracellularly, as well as extracellularly, is involved in the induction of significant neuronal apoptosis and may be one of the molecular mechanisms in HIV-1-induced encephalopathy... - Combination genetic therapy to inhibit HIV-1David S Strayer
Department of Pathology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Mol Ther 5:33-41. 2002..Thus, combination gene therapies may inhibit HIV-1 better than single agents, and rSV40s may facilitate delivery of multigene therapeutics... - Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infectionsGiuseppe Nunnari
Dorrance H. Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS 16:39-45. 2002..Thus, these findings suggest that mainly latent HIV-1 occurs in seminal cells of men on suppressive HAART, which may be a compartment-specific mechanism of residual HIV-1 disease... - Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cellsHeather D Foley
The Dorrance H. Hamilton Laboratories, Center for Human Virology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
J Virol 76:19-31. 2002..The ability of RV-based vectors to infect professional antigen-presenting cells efficiently further emphasizes the potential use of recombinant RVs as vaccines... - Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJNaiming Zhou
The Dorrance H Hamilton Laboratories, Thomas Jefferson University, Jefferson Medical College, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Virology 307:22-36. 2003..The CNS represents a unique reservoir site for HIV-1. As such, molecular therapeutics and small molecular inhibitors of HIV-1 entry via this unique CNS receptor are now able to be rationally designed... - Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1Roger J Pomerantz
Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
HIV Clin Trials 4:137-43. 2003..An understanding of these sanctuaries and reservoirs for HIV-1 in the setting of virally suppressive HAART will be critical in developing new approaches to induce HIV-1 remissions or the possibility of viral eradication in the future... - Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler
New York University Medical Center, New York, NY 10016, USA
J Acquir Immune Defic Syndr 36:576-87. 2004..Approaches to preserve or enhance immune function in HIV-1 infection are needed... - Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector designAdrienne Goodrich
Center for Human Virology and Biodefense, Thomas Jefferson University, Philadelphia, PA 19107, USA
Mol Ther 9:557-65. 2004..The results of this study present key information on spliced RNA and its encapsidation, as well as data for the construction of a new generation of SNV-derived retroviral vectors... - Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseasesPhilip M McKenna
The Dorrance H. Hamilton Laboratories, Center for Human Virology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107-6799, USA
Curr HIV Res 1:229-37. 2003..This review gives an overview of the use of RV and VSV as promising new candidates in the fight against HIV-1 and other human diseases... - HIV-1 infection and genomics: sorting out the complexityRoger J Pomerantz
J Infect Dis 189:567-71. 2004 - Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individualsJoseph A Desimone
Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS Patient Care STDS 17:617-22. 2003..Finally, we propose recommendations and a clinical algorithm regarding the optimal means of treatment of MAC immune reconstitution disease during HIV-1 infection... - Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAARTMiguel Otero
The Dorrance H. Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS Res Hum Retroviruses 19:1097-103. 2003..These populations of peripheral blood DCs are likely not a major HIV-1 reservoir in patients on HAART with clinically undetectable plasma viral RNA... - Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vectorPierre Cordelier
Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Philadelphia, PA 19107, USA
J Interferon Cytokine Res 23:477-88. 2003..These findings may have implications for therapy of HIV-1 infection in the CNS... - Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivoJoseph Kulkosky
The Dorrance H Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Virology 314:617-29. 2003.... - Cell-type-specific gene delivery into neuronal cells in vitro and in vivoZahida Parveen
The Dorrance H Hamilton Laboratories, Division of Infectious Diseases, Center for Human Virology and Biodefense, and Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Virology 314:74-83. 2003..Cell-type-specific gene delivery into neurons may present quite specific gene therapy approaches for many degenerative diseases of the brain... - Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1Naiming Zhou
The Dorrance H. Hamilton Laboratories, Thomas Jefferson University, Jefferson Medical College, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, 1020 Locust Street, Suite 329, Philadelphia, PA 19107, USA
Virology 312:196-203. 2003..ALX40-4C, as an antagonist to APJ, directly binds to and prevents use of APJ as a HIV-1 co-receptor. Thus, ALX-4C has potential utility for further elucidation of HIV-1 neuropathogenesis and therapy of HIV-1-induced encephalopathy... - HIV: cross-talk and viral reservoirsRoger J Pomerantz
Nature 424:136-7. 2003 - Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profileGiuseppe Nunnari
University of Catania, Italy
Ann Intern Med 139:26-30. 2003..Progression to AIDS is slower in persons infected with both HIV-1 and GB virus C (GBV-C), also known as hepatitis G virus... - The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNAHui Zhang
The Dorrance H Hamilton Laboratories, Center for Human Virology and Biodefense, Division of Infectious Diseases and Environmental Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Nature 424:94-8. 2003..Importantly, the accumulation of CEM15-mediated non-lethal hypermutation in the replicating viral genome could potently contribute to the genetic variation of primate lentiviral populations... - Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradicationRoger J Pomerantz
Dorrance H Hamilton Laboratories and Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
Clin Infect Dis 34:91-7. 2002....
Research Grants
- MOLECULAR THERAPEUTICS FOR HIV1 INDUCED CNS DYSFUNCTIONRoger Pomerantz; Fiscal Year: 2002..As such, these specific aims hope to yield critical data in the design of therapeutics to alter HIV-1 infection in CNS-based cells, and potentially for ADC in HIV-1-infected-individuals. ..
- Retroviral Vectors for Gene Therapy of HIV-1 InfectionRoger Pomerantz; Fiscal Year: 2003..abstract_text> ..
- HIV/AIDS Intravirion Reverse Transcription and VirucidesRoger Pomerantz; Fiscal Year: 2004..These studies are also designed to move analysis of intravirion reverse transcription from the bench towards clinical utility in altering sexual transmission of human lentiviruses. ..
- Alcohol's Effects on HIV-1 and the Blood: Brain BarrierRoger Pomerantz; Fiscal Year: 2004..With these inter-related specific aims, it is proposed that a series of new technologies will be combined towards determining the precise effects of Etoh on inducing alterations in the BBB with HW-l I infection of these cells. ..
- Gene Therapy of AIDS DementiaRoger Pomerantz; Fiscal Year: 2004..abstract_text> ..
- Effects of HIV -1 Proteins on the Blood/ Brain BarrierRoger Pomerantz; Fiscal Year: 2004....